Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trial

References

• Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. World health organization-coordinated global rotavirus surveillance n. global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2016;62:S96–S105.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rotavirus vaccines. WHO Position Paper, February 1, 2013.
   Google Scholar
• Jin H, Wang B, Fang Z, Duan Z, Gao Q, Liu N, Zhang L, Qian Y, Gong S, Zhu Q, et al. Hospital-based study of the economic burden associated with rotavirus diarrhea in eastern China. Vaccine. 2011;29:7801–06. doi:10.1016/j.vaccine.2011.07.104.
   PubMed Web of Science ®Google Scholar
• Zhang J, Duan Z, Payne DC, Yen C, Pan X, Chang Z, Liu N, Ye J, Ren X, Tate JE, et al. Rotavirus-specific and overall diarrhea mortality in chinese children younger than 5 years: 2003 to 2012. Pediatr Infect Dis J. 2015;34:e233–7. doi:10.1097/INF.0000000000000799.
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the immunization strategic advisory group of experts. 2009 April;84(23):220–36.
   Google Scholar
• Burke RM, Tate JE, Kirkwood CD, Steele AD, Parashar UD. Current and new rotavirus vaccines. Curr Opin Infect Dis. 2019;32:435–44. doi:10.1097/QCO.0000000000000572.
   PubMed Web of Science ®Google Scholar
• Burnett E, Parashar UD, Tate JE. Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006–2019. J Infect Dis. 2020 October;222(10):1731–39. doi:10.1093/infdis/jiaa081.
   PubMed Web of Science ®Google Scholar
• Mo Z, Ma X, Luo P, Mo Y, Kaplan SS, Shou Q, Zheng M, Hille DA, Arnold BA, Liao X, et al. Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. Vaccine. 2019;37:1836–43. doi:10.1016/j.vaccine.2019.02.018.
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis. 2005;192(Suppl 1):S22–9.
   PubMed Web of Science ®Google Scholar
• Gutierrez G. [The National Program to Control Diarrheal Diseases: its impact on health and health services]. Salud Publica Mex. 1994;36:127–28.
   PubMed Web of Science ®Google Scholar
• Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol. 1985;53:949–54. doi:10.1128/JVI.53.3.949-954.1985.
   PubMed Web of Science ®Google Scholar
• Paul A, Babji S, Sowmyanarayanan TV, Dhingra MS, Ramani S, Kattula D, Kang G. Human and bovine rotavirus strain antigens for evaluation of immunogenicity in a randomized, double-blind, placebo-controlled trial of a single dose live attenuated tetravalent, bovine-human-reassortant, oral rotavirus vaccine in Indian adults. Vaccine. 2014;32:3094–100. doi:10.1016/j.vaccine.2014.03.013.
   PubMed Web of Science ®Google Scholar
• Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, Stephens I, Karron R, Deforest A, Kapikian AZ, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine. 2001;19:4676–84. doi:10.1016/S0264-410X(01)00242-0.
   PubMed Web of Science ®Google Scholar
• Clements-Mann ML, Makhene MK, Mrukowicz J, Wright PF, Hoshino Y, Midthun K, Sperber E, Karron R, Kapikian AZ. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine. 1999;17:2715–25. doi:10.1016/S0264-410X(98)00497-6.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest B, Hoshino Y, Chanock R, Kapikian A, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis. 2006;194:370–76. doi:10.1086/505151.
   PubMed Web of Science ®Google Scholar
• Fujii Y, Doan YH, Wahyuni RM, Lusida MI, Utsumi T, Shoji I, Katayama K.  Improvement of rotavirus genotyping method by using the semi-nested multiplex-PCR with new primer set. Front Microbiol. 2019 March;10:647.
   PubMed Web of Science ®Google Scholar
• Nationa Medical Products Administration. https://www.nmpa.gov.cn/index.html
   Google Scholar
• Li RC, Li YP, Mo ZJ, Luo D, Huang T, Kong JL, Wang L-H, Song N-S, Liu A, Zhang H, et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies. Hum Vaccin Immunother. 2013;9:1638–42. doi:10.4161/hv.25076.
   PubMed Web of Science ®Google Scholar
• Dhingra MS, Kundu R, Gupta M, Kanungo S, Ganguly N, Singh MP, Bhattacharya MK, Ghosh R, Kumar R, Sur D, et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine. 2014;32(Suppl 1):A117–23. doi:10.1016/j.vaccine.2014.03.069.
   PubMed Web of Science ®Google Scholar
• Anil K, Desai S, Bhamare C, Dharmadhikari A, Madhusudhan RL, Patel J, Kulkarni PS. Safety and tolerability of a liquid bovine rotavirus pentavalent vaccine (LBRV-PV) in adults. Vaccine. 2018;36:1542–44. doi:10.1016/j.vaccine.2018.02.024.
   PubMed Web of Science ®Google Scholar
• Kanchan V, Zaman K, Aziz AB, Zaman SF, Zaman F, Haque W, Khanam M, Karim MM, Kale S, Ali SK, et al. A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants. Hum Vaccin Immunother. 2020 Mar 3;16(3):693–702. doi:10.1080/21645515.2019.1664239. Epub 2019 Oct 29.
   PubMed Web of Science ®Google Scholar
• Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH, et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011;29:6335–41. doi:10.1016/j.vaccine.2011.05.017.
   PubMed Web of Science ®Google Scholar
• Iwata S, Nakata S, Ukae S, Koizumi Y, Morita Y, Kuroki H, Tanaka Y, Shizuya T, Schödel F, Brown ML, et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Hum Vaccin Immunother. 2013;9:1626–33. doi:10.4161/hv.24846.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33. doi:10.1056/NEJMoa052664.
   PubMed Web of Science ®Google Scholar
• Mo Z, Mo Y, Li M, Tao J, Yang X, Kong J, Wei D, Fu B, Liao X, Chu J, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. Vaccine. 2017;35:5897–904. doi:10.1016/j.vaccine.2017.08.081.
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Desai S, Tewari T, Kawade A, Goyal N, Garg BS, Kumar D, Kanungo S, Kamat V, Kang G, et al. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35:6228–37. doi:10.1016/j.vaccine.2017.09.014.
   PubMed Web of Science ®Google Scholar
• Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014;383:2136–43. doi:10.1016/S0140-6736(13)62630-6.
   PubMed Web of Science ®Google Scholar
• Zade JK, Kulkarni PS, Desai SA, Sabale RN, Naik SP, Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine. 2014;32(Suppl 1):A124–8. doi:10.1016/j.vaccine.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, Datta S, P.V. S, Delem A, Han HH, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin. 2009;5:414–19. doi:10.4161/hv.5.6.8176.
   PubMed Web of Science ®Google Scholar
• Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, Mishra A, Singh S, Vrati S. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2009;200:421–29. doi:10.1086/600104.
   PubMed Web of Science ®Google Scholar
• Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine. 2006;24:2718–31. doi:10.1016/j.vaccine.2005.12.048.
   PubMed Web of Science ®Google Scholar
• Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2002;34:1351–61. doi:10.1086/340103.
   PubMed Web of Science ®Google Scholar
• Li RC, Huang T, Li Y, Wang LH, Tao J, Fu B, Si G, Nong Y, Mo Z, Liao X, et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Hum Vaccin Immunother. 2016;12:785–93. doi:10.1080/21645515.2015.1085143.
   PubMed Web of Science ®Google Scholar
• Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 2008;8:642–49. doi:10.1016/S1473-3099(08)70231-7.
   PubMed Web of Science ®Google Scholar